Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
Nivolumab bij gevorderd hepatocellulair carcinoom: CheckMate 040
jul 2017 | Immuuntherapie, Maag-darm-leveroncologie